7 Jun 2024 • A recent study suggests resistin is a prognostic and therapeutic biomarker for pulmonary arterial hypertension (PAH).

The potential use of resistin, a cytokine, as a genetic and biological marker for disease severity and survival in patients with PAH was evaluated. In a cohort of 1121 adults with PAH, resistin levels were measured and found to be significantly higher in PAH patients compared to controls.

• High resistin levels were associated with older age, reduced cardiac performance, and increased risk of death (hazard ratio: 2.6).
• Mutant carriers of certain genetic variants also had higher resistin levels.
• Machine-learning algorithms were used to develop a survival model, which included resistin levels as a prognostic factor.

This study highlights the importance of resistin as a potential biomarker for PAH prognosis and suggests it could be a target for therapeutic interventions.

Source: BMC | Read full story